Results 171 to 180 of about 53,055 (281)

Stabilization of spray-dried monoclonal antibody formulations with polymeric excipients. [PDF]

J Pharm Sci
Patil CD, Arte KS, Sapkota R, Huang Y, Kafle N, Liu J, Munson EJ, Renawala HK, Zhou QT, Qu LL.   +9 more
europepmc   +1 more source

Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation Test

Allergy, EarlyView.
ABSTRACT Basophils, the least abundant leukocytes, are increasingly recognised as potent immunomodulators. Upon activation, they rapidly release preformed granule‐associated mediators including histamine and lipid mediators such as LTC4, while cytokine production occurs over a longer timescale, contributing to downstream immune responses.
Jitesh Chauhan, Sofia Vlasova, Alicia Chenoweth, Debra H. Josephs, Heather J. Bax, Sophia N. Karagiannis   +5 more
wiley   +1 more source

Microplastics matter: practical implications of the EU REACH restriction for the pharmaceutical industry. [PDF]

Front Drug Deliv
Janssen PHM, Rijpkema WA, Bisharat L, Orbons M, Jaspers M, Dickhoff BHJ.   +5 more
europepmc   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source

Preformulation Studies and Rational Design of an Ointment Containing a Postbiotic Metabolite of Procyanidins for Topical Use. [PDF]

Pharmaceutics
Todryk T, Budnicka M, Pajchel L, Kierońska H, Dawidowski M, Stępień KA, Giebułtowicz J, Granica S, Kolmas J, Piwowarski JP.   +9 more
europepmc   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres, Cristobalina Mayorga, Elizabeth J. Phillips, Adriana Ariza, Annick Barbaud, Patrizia Bonadonna, Mariana Castells, Gülfem Çelik, Knut Brockow, Lene H. Garvey, Inmaculada Doña, Jean‐Christoph Caubet, Francesca Mori, Jason Trubiano, Giorgia Marta, Antonino Romano, Ingrid Terreehorst, Asli Gelincik, Philip H. Li, Vito Sabato   +19 more
wiley   +1 more source

Translational Barriers to Pharmaceutical Excipient Readiness in Marine-Derived Polymers. [PDF]

Polymers (Basel)
Herdiana Y, Mahmood S, Halimah E, Sofian FF.   +3 more
europepmc   +1 more source

A single‐center prospective observational study evaluating the efficacy and safety of tirbanibulin 1% in actinic keratoses in immunosuppressed patients: the ESTIMATE study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Actinic keratoses (AKs) are common precursors to squamous cell carcinoma and pose a heightened risk in immunosuppressed patients, such as organ transplant recipients (OTRs). Patients and methods This prospective, monocentric, single‐arm observational study investigated the safety and efficacy of topical tirbanibulin 1% ointment in ...
Elisa Zavattaro, Federica Veronese, Vanessa Tarantino, Chiara Airoldi, Paola Savoia   +4 more
wiley   +1 more source

Declared Inactive Ingredients in US Oral Drug Listings: A Reproducible Census of Prevalence, Labeling Coverage, and Within-Name Variation. [PDF]

Cureus
Staiger B.
europepmc   +1 more source

First‐In‐Human Study of Mirogabalin (BM2216) Sustained‐Release Tablets: Safety, Tolerability, Pharmacokinetics, Food Effect and Dose Proportionality With Comparison to Mirogabalin Besylate in Healthy Participants

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To characterise the pharmacokinetics (PKs) and safety of BM2216 sustained‐release (SR) tablets after single‐dose oral administration under fasted/fed conditions in healthy participants, assess the effect of food and dose proportionality, and compare the single and multiple‐dose PK of BM2216 SR tablets with mirogabalin besylate tablets to ...
Peiyang Song, Hongtao Zhao, Mingxue Zhu, Lei Wan, Yuan Chen, Zhongping Li, Chengyong Tang   +6 more
wiley   +1 more source